$HRMY
Harmony Biosciences Holdings, Inc.

2024 Q4 Form 10-Q Financial Statement

#000155837024013803 Filed on October 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $186.0M
YoY Change 16.08%
Cost Of Revenue $42.78M
YoY Change 32.46%
Gross Profit $143.3M
YoY Change 11.95%
Gross Profit Margin 77.01%
Selling, General & Admin $56.16M
YoY Change 22.19%
% of Gross Profit 39.2%
Research & Development $25.39M
YoY Change 45.08%
% of Gross Profit 17.72%
Depreciation & Amortization $5.968M
YoY Change -3.74%
% of Gross Profit 4.17%
Operating Expenses $81.55M
YoY Change 28.5%
Operating Profit $61.71M
YoY Change -4.34%
Interest Expense $584.0K
YoY Change -120.1%
% of Operating Profit 0.95%
Other Income/Expense, Net -$124.0K
YoY Change 2380.0%
Pretax Income $62.17M
YoY Change 19.95%
Income Tax $16.08M
% Of Pretax Income 25.86%
Net Earnings $46.09M
YoY Change 19.84%
Net Earnings / Revenue 24.78%
Basic Earnings Per Share $0.81
Diluted Earnings Per Share $0.79
COMMON SHARES
Basic Shares Outstanding 57.03M 56.83M
Diluted Shares Outstanding 58.10M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $410.5M
YoY Change 10.73%
Cash & Equivalents $387.4M
Short-Term Investments $23.11M
Other Short-Term Assets $7.455M
YoY Change 30.7%
Inventory $6.915M
Prepaid Expenses $16.06M
Receivables $81.50M
Other Receivables $0.00
Total Short-Term Assets $522.4M
YoY Change 12.83%
LONG-TERM ASSETS
Property, Plant & Equipment $750.0K
YoY Change 75.23%
Goodwill
YoY Change
Intangibles $119.2M
YoY Change -16.67%
Long-Term Investments $94.22M
YoY Change 39.18%
Other Assets $6.247M
YoY Change 120.28%
Total Long-Term Assets $405.7M
YoY Change 28.9%
TOTAL ASSETS
Total Short-Term Assets $522.4M
Total Long-Term Assets $405.7M
Total Assets $928.1M
YoY Change 19.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.53M
YoY Change 61.06%
Accrued Expenses $109.7M
YoY Change 50.73%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $15.00M
YoY Change 0.0%
Total Short-Term Liabilities $161.3M
YoY Change 43.48%
LONG-TERM LIABILITIES
Long-Term Debt $167.8M
YoY Change -7.84%
Other Long-Term Liabilities $2.205M
YoY Change 16.36%
Total Long-Term Liabilities $170.1M
YoY Change -7.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $161.3M
Total Long-Term Liabilities $170.1M
Total Liabilities $331.3M
YoY Change 11.77%
SHAREHOLDERS EQUITY
Retained Earnings -$47.26M
YoY Change -72.18%
Common Stock $643.6M
YoY Change -1.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $596.8M
YoY Change
Total Liabilities & Shareholders Equity $928.1M
YoY Change 19.33%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $46.09M
YoY Change 19.84%
Depreciation, Depletion And Amortization $5.968M
YoY Change -3.74%
Cash From Operating Activities $70.50M
YoY Change 11.73%
INVESTING ACTIVITIES
Capital Expenditures $3.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $748.0K
YoY Change -193.5%
Cash From Investing Activities $745.0K
YoY Change -193.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.175M
YoY Change -97.87%
NET CHANGE
Cash From Operating Activities 70.50M
Cash From Investing Activities 745.0K
Cash From Financing Activities -1.175M
Net Change In Cash 70.07M
YoY Change 873.21%
FREE CASH FLOW
Cash From Operating Activities $70.50M
Capital Expenditures $3.000K
Free Cash Flow $70.50M
YoY Change 11.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2024Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2024Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
dei Entity Central Index Key
EntityCentralIndexKey
0001802665
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
CY2024Q3 us-gaap Other Receivable After Allowance For Credit Loss Related Party Type Extensible Enumeration
OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2023Q4 us-gaap Other Receivable After Allowance For Credit Loss Related Party Type Extensible Enumeration
OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2024Q3 us-gaap Other Liabilities
OtherLiabilities
0
CY2023Q4 us-gaap Other Liabilities
OtherLiabilities
0
CY2024Q3 us-gaap Other Liability Related Party Type Extensible Enumeration
OtherLiabilityRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2023Q4 us-gaap Other Liability Related Party Type Extensible Enumeration
OtherLiabilityRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
CY2024Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39450
dei Entity Registrant Name
EntityRegistrantName
HARMONY BIOSCIENCES HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2279923
dei Entity Address Address Line1
EntityAddressAddressLine1
630 W.
dei Entity Address Address Line2
EntityAddressAddressLine2
Germantown Pike
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 215
dei Entity Address City Or Town
EntityAddressCityOrTown
Plymouth Meeting
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19462
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
539-9800
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 value per share
dei Trading Symbol
TradingSymbol
HRMY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
57031297
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
387367000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
311660000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
23109000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
41800000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
81502000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
74140000
CY2024Q3 us-gaap Inventory Net
InventoryNet
6915000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5363000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
16057000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
12570000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
7455000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5537000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
522405000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
451070000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
750000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
371000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
270000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
270000
CY2024Q3 us-gaap Long Term Investments
LongTermInvestments
94222000
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
72169000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
119225000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
137108000
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
185016000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
144162000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6247000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6298000
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
405730000
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
360378000
CY2024Q3 us-gaap Assets
Assets
928135000
CY2023Q4 us-gaap Assets
Assets
811448000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10532000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17730000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14224000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23747000
CY2024Q3 hrmy Accrued Liabilities Other Than Accrued Compensation Current
AccruedLiabilitiesOtherThanAccruedCompensationCurrent
109673000
CY2023Q4 hrmy Accrued Liabilities Other Than Accrued Compensation Current
AccruedLiabilitiesOtherThanAccruedCompensationCurrent
99494000
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
15000000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
15000000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
11850000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7810000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
161279000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6247000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6298000
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
405730000
CY2023Q4 us-gaap Assets
Assets
811448000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10532000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17730000
CY2024Q3 hrmy Accrued Liabilities Other Than Accrued Compensation Current
AccruedLiabilitiesOtherThanAccruedCompensationCurrent
109673000
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
15000000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
11850000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7810000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
161279000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
163781000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
167847000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
178566000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2205000
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
170052000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
163781000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
167847000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
178566000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2205000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2109000
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
170052000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
180675000
CY2024Q3 us-gaap Liabilities
Liabilities
331331000
CY2023Q4 us-gaap Liabilities
Liabilities
344456000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57030897
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57030897
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56769081
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56769081
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
643563000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
610266000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
499000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47259000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143277000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
596804000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
466992000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
928135000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
811448000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
186038000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
160268000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
513467000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
413610000
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
42778000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32296000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
102406000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
78084000
CY2024Q3 us-gaap Gross Profit
GrossProfit
143260000
CY2023Q3 us-gaap Gross Profit
GrossProfit
127972000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25387000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17499000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
111159000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45757000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
27576000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57030897
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57030897
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56769081
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56769081
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
643563000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
596804000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
466992000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
928135000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
811448000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
186038000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
160268000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
513467000
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
42778000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32296000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
102406000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
78084000
CY2024Q3 us-gaap Gross Profit
GrossProfit
143260000
CY2023Q3 us-gaap Gross Profit
GrossProfit
127972000
us-gaap Gross Profit
GrossProfit
411061000
us-gaap Gross Profit
GrossProfit
335526000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25387000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17499000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45757000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
27576000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
23418000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
83316000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
70518000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28587000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22546000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
81487000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
67417000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
81550000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
63463000
us-gaap Operating Expenses
OperatingExpenses
275962000
us-gaap Operating Expenses
OperatingExpenses
183692000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
61710000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
64509000
us-gaap Operating Income Loss
OperatingIncomeLoss
135099000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9766000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9766000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-124000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-228000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-34000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
23418000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
83316000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28587000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22546000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
81487000
us-gaap Operating Expenses
OperatingExpenses
275962000
us-gaap Operating Expenses
OperatingExpenses
183692000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
61710000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
64509000
us-gaap Operating Income Loss
OperatingIncomeLoss
135099000
us-gaap Operating Income Loss
OperatingIncomeLoss
151834000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9766000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9766000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-124000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-228000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-34000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4348000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
7012000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
13287000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
18961000
CY2024Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
4932000
CY2023Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
4106000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
14065000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
10634000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
62170000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
51832000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
135649000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
133707000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16077000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13371000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39631000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31461000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
46093000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
38461000
us-gaap Net Income Loss
NetIncomeLoss
96018000
us-gaap Net Income Loss
NetIncomeLoss
102246000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
733000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
497000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-365000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
46826000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
38467000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
101881000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.81
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.71
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4348000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
7012000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
13287000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
18961000
CY2024Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
4932000
CY2023Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
4106000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
14065000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
10634000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
62170000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
51832000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
133707000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16077000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13371000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39631000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31461000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
46093000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
38461000
us-gaap Net Income Loss
NetIncomeLoss
96018000
us-gaap Net Income Loss
NetIncomeLoss
102246000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
733000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
497000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-365000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
46826000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
38467000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
96515000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
101881000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.81
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.71
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.68
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56870234
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59863102
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56815167
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59856941
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58103963
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60681676
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57754016
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60892992
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
466992000
us-gaap Net Income Loss
NetIncomeLoss
96018000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
497000
hrmy Stock Issued During Period Value Stock Options And Restricted Stock Units Exercised
StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised
767000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32530000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
596804000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.68
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56870234
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59863102
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56815167
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59856941
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58103963
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60681676
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57754016
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60892992
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
466992000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
497000
hrmy Stock Issued During Period Value Stock Options And Restricted Stock Units Exercised
StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised
767000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32530000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
596804000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
538583000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
46093000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
733000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
347000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11048000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
596804000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
402838000
us-gaap Net Income Loss
NetIncomeLoss
102246000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-365000
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
50543000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4314000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22842000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
481332000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
485172000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
38461000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000
CY2023Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
50543000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
245000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7991000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
481332000
us-gaap Profit Loss
ProfitLoss
96018000
us-gaap Profit Loss
ProfitLoss
102246000
us-gaap Depreciation
Depreciation
261000
us-gaap Depreciation
Depreciation
350000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17883000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17884000
hrmy In Process Research And Development Acquired
InProcessResearchAndDevelopmentAcquired
42595000
us-gaap Share Based Compensation
ShareBasedCompensation
32530000
us-gaap Share Based Compensation
ShareBasedCompensation
22842000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
315000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
-531000
hrmy Adjustment For Amortization Of Debt Issuance Costs
AdjustmentForAmortizationOfDebtIssuanceCosts
531000
hrmy Adjustment For Amortization Of Debt Issuance Costs
AdjustmentForAmortizationOfDebtIssuanceCosts
2089000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
538583000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
46093000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
733000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
347000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11048000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
596804000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
402838000
us-gaap Net Income Loss
NetIncomeLoss
102246000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-365000
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
50543000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4314000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22842000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
481332000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
485172000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
38461000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000
CY2023Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
50543000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
245000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7991000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
481332000
us-gaap Profit Loss
ProfitLoss
96018000
us-gaap Profit Loss
ProfitLoss
102246000
us-gaap Depreciation
Depreciation
261000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17883000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17884000
hrmy In Process Research And Development Acquired
InProcessResearchAndDevelopmentAcquired
42595000
us-gaap Share Based Compensation
ShareBasedCompensation
32530000
us-gaap Share Based Compensation
ShareBasedCompensation
22842000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
315000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
-531000
hrmy Adjustment For Amortization Of Debt Issuance Costs
AdjustmentForAmortizationOfDebtIssuanceCosts
531000
hrmy Adjustment For Amortization Of Debt Issuance Costs
AdjustmentForAmortizationOfDebtIssuanceCosts
2089000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-22586000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-14542000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1770000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2031000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9766000
us-gaap Other Noncash Expense
OtherNoncashExpense
1619000
us-gaap Other Noncash Expense
OtherNoncashExpense
1258000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7362000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12524000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1552000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
790000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4851000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1759000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-8596000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2753000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-776000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
15711000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
144259000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-22586000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-14542000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1770000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2031000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9766000
us-gaap Other Noncash Expense
OtherNoncashExpense
1619000
us-gaap Other Noncash Expense
OtherNoncashExpense
1258000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7362000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12524000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1552000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
790000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4851000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1759000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-8596000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2753000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-776000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
15711000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
144259000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
142722000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
69604000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
105856000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
68516000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
95687000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
640000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
205000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
33069000
hrmy Payment Of License Fee Investing Activities
PaymentOfLicenseFeeInvestingActivities
25500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60297000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10374000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
200000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2997000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
196500000
hrmy Payments Of Extinguishment Of Debt Exit Fees
PaymentsOfExtinguishmentOfDebtExitFees
5846000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
11250000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
50000000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
269000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
514000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3264000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4828000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8255000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-52029000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
75707000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
80319000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
311930000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
244534000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
387637000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
324853000
us-gaap Interest Paid Net
InterestPaidNet
13170000
us-gaap Interest Paid Net
InterestPaidNet
15653000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
142722000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
69604000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
105856000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
68516000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
95687000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
640000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
205000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
33069000
hrmy Payment Of License Fee Investing Activities
PaymentOfLicenseFeeInvestingActivities
25500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60297000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10374000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
200000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2997000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
196500000
hrmy Payments Of Extinguishment Of Debt Exit Fees
PaymentsOfExtinguishmentOfDebtExitFees
5846000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
11250000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
50000000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
269000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
514000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3264000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4828000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8255000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-52029000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
75707000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
80319000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
311930000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
244534000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
387637000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
324853000
us-gaap Interest Paid Net
InterestPaidNet
13170000
us-gaap Interest Paid Net
InterestPaidNet
15653000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
58549000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
36543000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
58549000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
36543000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47259000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143277000
CY2024Q3 us-gaap Investments And Cash
InvestmentsAndCash
504698000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reclassifications</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain prior period amounts within the unaudited condensed consolidated statements of operations and comprehensive income have been reclassified to conform to current period presentation. In particular, interest expense and interest income were previously classified together as interest expense, net and are now separately classified as interest expense and interest income, respectively. The reclassification of these items had no impact on net income, earnings per share or accumulated deficit in current or prior periods.</p>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47259000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143277000
CY2024Q3 us-gaap Investments And Cash
InvestmentsAndCash
504698000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reclassifications</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain prior period amounts within the unaudited condensed consolidated statements of operations and comprehensive income have been reclassified to conform to current period presentation. In particular, interest expense and interest income were previously classified together as interest expense, net and are now separately classified as interest expense and interest income, respectively. The reclassification of these items had no impact on net income, earnings per share or accumulated deficit in current or prior periods.</p>
hrmy Number Of Approved Commercial Products
NumberOfApprovedCommercialProducts
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes. </p>
hrmy Number Of Approved Commercial Products
NumberOfApprovedCommercialProducts
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes. </p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
387367000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
311660000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
270000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
387637000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
311930000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
387367000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
311660000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
270000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
270000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
387637000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
311930000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s cash and money market funds are held in five financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored, and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of September 30, 2024, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 34% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 34% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 32% of gross accounts receivable. As of December 31, 2023, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 39% of gross accounts receivable, CVS Caremark, which accounted for 32% of gross accounts receivable; and Pantherx, which accounted for 29% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2024, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 40% of gross product revenue; Accredo accounted for 33% of gross product revenue; and Pantherx accounted for 27% of gross product revenue. For the nine months ended September 30, 2023, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 37% of gross product revenue; Accredo accounted for 32% of gross product revenue; and Pantherx accounted for 31% of gross product revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company depends on a single supplier of the active pharmaceutical ingredient (“API”) for its commercial product, WAKIX, and single API suppliers for each of its potential product candidates. </p>
hrmy Concentrations Of Risk Number Of Financial Institutions
ConcentrationsOfRiskNumberOfFinancialInstitutions
5
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q4 us-gaap Asset Acquisition Consideration Transferred Transaction Cost
AssetAcquisitionConsiderationTransferredTransactionCost
2645000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s cash and money market funds are held in five financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored, and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of September 30, 2024, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 34% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 34% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 32% of gross accounts receivable. As of December 31, 2023, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 39% of gross accounts receivable, CVS Caremark, which accounted for 32% of gross accounts receivable; and Pantherx, which accounted for 29% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2024, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 40% of gross product revenue; Accredo accounted for 33% of gross product revenue; and Pantherx accounted for 27% of gross product revenue. For the nine months ended September 30, 2023, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 37% of gross product revenue; Accredo accounted for 32% of gross product revenue; and Pantherx accounted for 31% of gross product revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company depends on a single supplier of the active pharmaceutical ingredient (“API”) for its commercial product, WAKIX, and single API suppliers for each of its potential product candidates. </p>
hrmy Concentrations Of Risk Number Of Financial Institutions
ConcentrationsOfRiskNumberOfFinancialInstitutions
5
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q4 us-gaap Asset Acquisition Consideration Transferred Transaction Cost
AssetAcquisitionConsiderationTransferredTransactionCost
2645000
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
413715000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
358538000
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1033000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1060000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
2549000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2020000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3333000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2283000
CY2024Q3 us-gaap Inventory Net
InventoryNet
6915000
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
413715000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
358538000
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1033000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1060000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
2549000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2020000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3333000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2283000
CY2024Q3 us-gaap Inventory Net
InventoryNet
6915000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5363000
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5961000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5962000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17883000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17884000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
5961000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
23845000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
23845000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
23845000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
23845000
CY2024Q3 hrmy Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
17884000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
119225000
CY2024Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
215000000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
215000000
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
95775000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
77892000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
119225000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
137108000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5363000
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5961000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5962000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17883000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17884000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
5961000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
23845000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
23845000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
23845000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
23845000
CY2024Q3 hrmy Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
17884000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
119225000
CY2024Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
215000000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
215000000
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
95775000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
77892000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
119225000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
137108000
CY2024Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
40295000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
40419000
CY2024Q3 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
45837000
CY2023Q4 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
38842000
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
2941000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3354000
CY2024Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
3507000
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2354000
CY2024Q3 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
8011000
CY2023Q4 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
9835000
CY2024Q3 hrmy Accrued Milestone Payments Current
AccruedMilestonePaymentsCurrent
1000000
CY2024Q3 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
5241000
CY2023Q4 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
2195000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2841000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2495000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
109673000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
99494000
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
185000000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
196250000
CY2024Q3 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
2153000
CY2023Q4 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
2684000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
182847000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
193566000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
167847000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
178566000
CY2024Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
40295000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
40419000
CY2024Q3 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
45837000
CY2023Q4 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
38842000
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
2941000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3354000
CY2024Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
3507000
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2354000
CY2024Q3 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
8011000
CY2023Q4 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
9835000
CY2024Q3 hrmy Accrued Milestone Payments Current
AccruedMilestonePaymentsCurrent
1000000
CY2024Q3 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
5241000
CY2023Q4 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
2195000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2841000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2495000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
109673000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
99494000
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
185000000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
196250000
CY2024Q3 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
2153000
CY2023Q4 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
2684000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
182847000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
193566000
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
15000000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
15000000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
167847000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
178566000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3750000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
16250000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20000000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
125000000
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
185000000
CY2024Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4173000
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4791000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
12756000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
15900000
CY2024Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
175000
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2221000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
531000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3061000
CY2024Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4348000
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
7012000
us-gaap Interest Expense Debt
InterestExpenseDebt
13287000
us-gaap Interest Expense Debt
InterestExpenseDebt
18961000
CY2018Q2 hrmy Operating Lease Additional Office Space Leased One
OperatingLeaseAdditionalOfficeSpaceLeasedOne
13000
CY2018Q2 hrmy Operating Lease Additional Office Space Leased Two
OperatingLeaseAdditionalOfficeSpaceLeasedTwo
7000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
491000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
473000
us-gaap Operating Lease Cost
OperatingLeaseCost
1622000
us-gaap Operating Lease Cost
OperatingLeaseCost
1295000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0766
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2320000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3750000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
16250000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20000000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
125000000
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4791000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
12756000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
15900000
CY2024Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
175000
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2221000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
531000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3061000
CY2024Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4348000
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
7012000
us-gaap Interest Expense Debt
InterestExpenseDebt
13287000
us-gaap Interest Expense Debt
InterestExpenseDebt
18961000
CY2018Q2 hrmy Operating Lease Office Space
OperatingLeaseOfficeSpace
15000
CY2018Q2 hrmy Operating Lease Additional Office Space Leased One
OperatingLeaseAdditionalOfficeSpaceLeasedOne
13000
CY2018Q2 hrmy Operating Lease Additional Office Space Leased Two
OperatingLeaseAdditionalOfficeSpaceLeasedTwo
7000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
491000
us-gaap Operating Lease Cost
OperatingLeaseCost
1622000
us-gaap Operating Lease Cost
OperatingLeaseCost
1295000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0766
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2320000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2344000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1532000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1437000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
863000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1082000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2395000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2519000
us-gaap Operating Lease Payments
OperatingLeasePayments
1623000
us-gaap Operating Lease Payments
OperatingLeasePayments
1448000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1612000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1592000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2344000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1532000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1437000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2395000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2519000
us-gaap Operating Lease Payments
OperatingLeasePayments
1623000
us-gaap Operating Lease Payments
OperatingLeasePayments
1448000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1612000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
525000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1334000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
597000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
91000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2547000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
152000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2395000
CY2024Q3 hrmy Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6316422
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.47
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M1D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1361346
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
30.66
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
178611
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
16.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
86394
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
34.90
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7412763
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.49
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M1D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
72791000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4324302
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
30.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
49434000
CY2023Q4 hrmy Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms
P5Y3M25D
hrmy Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms
P4Y6M25D
hrmy Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerms
P4Y6M7D
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
525000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1334000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
597000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
91000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2547000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
152000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2395000
CY2024Q3 hrmy Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6316422
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.47
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M1D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1361346
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
30.66
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
178611
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
16.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
86394
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
34.90
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7412763
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.49
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M1D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
72791000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4324302
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
30.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
49434000
CY2023Q4 hrmy Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms
P5Y3M25D
hrmy Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms
P4Y6M25D
hrmy Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerms
P4Y6M7D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.6984
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7298
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7487
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8078
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0351
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0465
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0342
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0462
hrmy Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount
0.0000
CY2023 hrmy Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount
0.0000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11448000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7957000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32845000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22311000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
46093000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
38461000
us-gaap Net Income Loss
NetIncomeLoss
96018000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.6984
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7298
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0351
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0465
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0342
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11448000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7957000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32845000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22311000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
46093000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
38461000
us-gaap Net Income Loss
NetIncomeLoss
96018000
us-gaap Net Income Loss
NetIncomeLoss
102246000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.81
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.71
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.68
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56870234
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59863102
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56815167
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59856941
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57754016
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60892992
us-gaap Net Income Loss
NetIncomeLoss
102246000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.81
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.71
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.68
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56870234
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59863102
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56815167
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59856941
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58103963
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60681676
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57754016
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60892992
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1233729
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
818574
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
938849
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1036051
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6868642
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5518309
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7163522
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5300832
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1233729
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
818574
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
938849
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1036051
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6868642
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5518309
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7163522
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5300832
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.001
us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.002
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.051
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.063
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
CY2024Q3 hrmy Effective Income Tax Rate Reconciliation Tax Credits Percent
EffectiveIncomeTaxRateReconciliationTaxCreditsPercent
0.009
CY2023Q3 hrmy Effective Income Tax Rate Reconciliation Tax Credits Percent
EffectiveIncomeTaxRateReconciliationTaxCreditsPercent
-0.002
hrmy Effective Income Tax Rate Reconciliation Tax Credits Percent
EffectiveIncomeTaxRateReconciliationTaxCreditsPercent
0.012
hrmy Effective Income Tax Rate Reconciliation Tax Credits Percent
EffectiveIncomeTaxRateReconciliationTaxCreditsPercent
0.016
us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.025
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.004
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.004
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.006
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.003
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.001
us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.002
us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.009
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.051
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.063
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
CY2024Q3 hrmy Effective Income Tax Rate Reconciliation Tax Credits Percent
EffectiveIncomeTaxRateReconciliationTaxCreditsPercent
0.009
hrmy Effective Income Tax Rate Reconciliation Tax Credits Percent
EffectiveIncomeTaxRateReconciliationTaxCreditsPercent
0.012
hrmy Effective Income Tax Rate Reconciliation Tax Credits Percent
EffectiveIncomeTaxRateReconciliationTaxCreditsPercent
0.016
us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.025
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.004
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.004
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.006
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.003
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.259
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.258
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.292
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.235
CY2024Q3 us-gaap Other Receivables
OtherReceivables
0
CY2023Q4 us-gaap Other Receivables
OtherReceivables
0
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.258
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.235
CY2024Q3 us-gaap Other Receivables
OtherReceivables
0
CY2023Q4 us-gaap Other Receivables
OtherReceivables
0
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-013803-index-headers.html Edgar Link pending
0001558370-24-013803-index.html Edgar Link pending
0001558370-24-013803.txt Edgar Link pending
0001558370-24-013803-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hrmy-20240930.xsd Edgar Link pending
hrmy-20240930x10q.htm Edgar Link pending
hrmy-20240930xex31d1.htm Edgar Link pending
hrmy-20240930xex31d2.htm Edgar Link pending
hrmy-20240930xex32d1.htm Edgar Link pending
hrmy-20240930xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
hrmy-20240930_cal.xml Edgar Link unprocessable
hrmy-20240930_lab.xml Edgar Link unprocessable
hrmy-20240930_pre.xml Edgar Link unprocessable
hrmy-20240930x10q_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hrmy-20240930_def.xml Edgar Link unprocessable